Quick Answer
CORCEPT THERAPEUTICS INC reported R&D Expense of $254.91 million for fiscal year 2025.
CORCEPT THERAPEUTICS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $254.91M | +3.2% |
| 2024 | $246.89M | +33.9% |
| 2023 | $184.35M | +40.7% |
| 2022 | $130.99M | +15.0% |
| 2021 | $113.86M | -0.8% |
| 2020 | $114.76M | +28.9% |
| 2019 | $89.02M | +18.3% |
| 2018 | $75.25M | +86.4% |
| 2017 | $40.38M | +69.3% |
| 2016 | $23.84M | +54.6% |
| 2015 | $15.42M | -16.1% |
| 2014 | $18.37M | -10.2% |
| 2013 | $20.47M | +45.4% |
| 2012 | $14.07M | -33.0% |
| 2011 | $21.00M | +10.8% |
| 2010 | $18.95M | +31.6% |
| 2009 | $14.40M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $68.85M | +16.0% | +13.8% |
| June 30, 2025 | $60.47M | +2.9% | -0.4% |
| March 31, 2025 | $60.73M | +3.8% | +2.4% |
| September 30, 2024 | $59.34M | +30.4% | +1.0% |
| June 30, 2024 | $58.74M | +35.7% | +0.4% |
| March 31, 2024 | $58.51M | +43.2% | +28.5% |
| September 30, 2023 | $45.52M | +36.7% | +5.2% |
| June 30, 2023 | $43.28M | +31.8% | +5.9% |
- CORCEPT THERAPEUTICS INC showed an increase of +3.2% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, CORCEPT THERAPEUTICS INC’s r&d expense has grown by 1669.9% (from $14.40 million to $254.91 million).
- The most recent figure is from CORCEPT THERAPEUTICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: